瑞德西韦和氯喹有效抑制新近出现的新型冠状病毒(2019-nCoV)的体外

Title：Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) In Vitro

标题：瑞德西韦和氯喹有效抑制新近出现的新型冠状病毒(2019-nCoV)的体外

作者：M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong, G. Xiao

期刊：Cell Research

发表日期：2020年3月

DOI：10.1038/s41422-020-0282-0

摘要

本研究探讨了瑞德西韦和氯喹对新型冠状病毒（2019-nCoV）的体外抑制效果。研究结果表明，这两种药物在细胞实验中均表现出显著的抗病毒活性。瑞德西韦（Remdesivir）是一种核苷酸类似物，通过抑制病毒RNA聚合酶起作用。氯喹（Chloroquine）则是一种传统的抗疟药物，能提高内涵体和溶酶体的pH值，从而干扰病毒的复制过程。

Abstract

This study investigates the antiviral effects of remdesivir and chloroquine against the novel coronavirus (2019-nCoV) in vitro. The results indicate that both drugs exhibit significant antiviral activity in cell experiments. Remdesivir is a nucleotide analogue that inhibits viral RNA polymerase. Chloroquine is a traditional antimalarial drug that raises the pH of endosomes and lysosomes, thereby interfering with viral replication.

研究方法

病毒培养：使用Vero E6细胞系培养病毒。

药物处理：将瑞德西韦和氯喹分别加入细胞培养体系中。

抗病毒检测：通过qRT-PCR检测病毒RNA水平，评估药物的抑制效果。

Research Methods

Virus culture: The virus was cultured using the Vero E6 cell line.

Drug treatment: Remdesivir and chloroquine were added to the cell culture system.

Antiviral assay: The inhibitory effect of the drugs was evaluated by detecting viral RNA levels using qRT-PCR.

研究结果

瑞德西韦：在低浓度下（EC50 = 0.77 μM），能有效抑制2019-nCoV的复制。

氯喹：在更低浓度下（EC50 = 1.13 μM），也显示出显著的抗病毒活性。

Research Results

Remdesivir: At low concentrations (EC50 = 0.77 μM), it effectively inhibits the replication of 2019-nCoV.

Chloroquine: At lower concentrations (EC50 = 1.13 μM), it also shows significant antiviral activity.

结论

瑞德西韦和氯喹在体外均能有效抑制2019-nCoV的复制，提示这两种药物有潜力用于新冠肺炎的治疗。未来需要进一步的临床试验来验证它们的有效性和安全性。

Conclusion

Remdesivir and chloroquine can effectively inhibit the replication of 2019-nCoV in vitro, suggesting that these two drugs have potential for the treatment of COVID-19. Further clinical trials are needed to verify their efficacy and safety.

瑞德西韦和氯喹有效抑制新近出现的新型冠状病毒(2019-nCoV)的体外

相关产品